Go Pro
→ They proved it worked in '76. Then buried it. (From Behind the Markets) (Ad)tc pixel Free STIM Stock Alerts

Neuronetics (STIM) Financials

Neuronetics logo
$1.76 +0.10 (+6.02%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$1.75 -0.01 (-0.57%)
As of 07/10/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Neuronetics

Annual Income Statements for Neuronetics

This table shows Neuronetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Consolidated Net Income / (Loss)		 -11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Net Income / (Loss) Continuing Operations		 -11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Total Pre-Tax Income 		-11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Total Operating Income		 -9.34 -14 -20 -27 -22 -28 -35 -31 -35 -31
Total Gross Profit		 28 31 40 47 38 44 50 52 54 72
Total Revenue		 34 40 53 63 49 55 65 71 75 149
Operating Revenue		 34 40 53 63 49 55 65 71 75 149
Total Cost of Revenue		 6.62 9.63 12 15 12 12 15 20 21 77
Operating Cost of Revenue		 6.62 9.63 12 15 12 12 15 20 21 77
Total Operating Expenses		 37 44 60 74 60 71 85 82 89 104
Selling, General & Admin Expense		 6.93 8.57 14 17 18 26 26 25 30 50
Marketing Expense		 22 28 38 43 33 38 50 47 46 47
Research & Development Expense		 8.22 7.94 8.23 14 9.20 7.92 9.34 9.52 13 6.58
Total Other Income / (Expense), net		 -1.90 -2.45 -4.26 -2.11 -5.14 -3.63 -2.05 0.37 -9.16 -7.70
Interest Expense		 1.84 2.81 3.69 3.69 5.45 4.02 4.25 5.42 12 8.42
Other Income / (Expense), net		 -0.06 0.36 -0.58 1.57 0.30 0.39 2.20 5.79 2.55 0.72
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - - 0.00 0.00 -0.02 -0.14
Basic Earnings per Share		 ($76.95) ($86.34) ($2.69) ($1.58) ($1.46) ($1.22) ($1.38) ($1.05) ($1.38) ($0.59)
Weighted Average Basic Shares Outstanding		 146K 186K 8.95M 18.38M 18.84M 25.48M 26.90M 28.66M 31.73M 65.95M
Diluted Earnings per Share		 ($76.95) ($86.34) ($2.69) ($1.58) ($1.46) ($1.22) ($1.38) ($1.05) ($1.38) ($0.59)
Weighted Average Diluted Shares Outstanding		 146K 186K 8.95M 18.38M 18.84M 25.48M 26.90M 28.66M 31.73M 65.95M
Weighted Average Basic & Diluted Shares Outstanding		 146K 186K 8.95M 18.38M 18.84M 26.63M 28.36M 29.76M 65.81M 69.28M

Quarterly Income Statements for Neuronetics

This table shows Neuronetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.39 -5.38 -7.87 -9.83 -13 -13 -13 -10 -9.05 -7.16 -11
Consolidated Net Income / (Loss)		 -9.39 -5.38 -7.87 -9.83 -13 -13 -13 -9.84 -9.40 -7.21 -11
Net Income / (Loss) Continuing Operations		 -9.39 -5.38 -7.87 -9.83 -13 -13 -13 -9.84 -9.40 -7.21 -11
Total Pre-Tax Income 		-9.39 -5.38 -7.87 -9.83 -13 -13 -13 -9.84 -9.40 -7.21 -11
Total Operating Income		 -8.87 -4.43 -6.86 -8.51 -7.73 -11 -11 -8.06 -7.32 -5.04 -9.00
Total Gross Profit		 12 16 13 12 14 15 16 18 17 22 16
Total Revenue		 18 20 17 16 19 22 32 38 37 42 34
Operating Revenue		 18 20 17 16 19 22 32 38 37 42 34
Total Cost of Revenue		 6.12 4.54 4.33 4.27 4.53 7.60 16 20 20 20 18
Operating Cost of Revenue		 6.12 4.54 4.33 4.27 4.53 7.60 16 20 20 20 18
Total Operating Expenses		 21 20 20 21 22 26 27 26 24 27 25
Selling, General & Admin Expense		 6.34 6.28 5.96 6.15 7.44 11 13 12 11 13 13
Marketing Expense		 12 12 12 12 12 9.81 12 12 12 12 11
Research & Development Expense		 2.16 2.21 2.35 2.24 2.42 5.77 1.62 1.80 1.50 1.67 1.36
Total Other Income / (Expense), net		 -0.52 -0.95 -1.01 -1.33 -5.61 -1.21 -1.68 -1.78 -2.08 -2.16 -1.79
Interest Expense		 1.18 1.84 1.83 1.98 6.15 1.76 1.92 1.97 2.21 2.32 2.81
Other Income / (Expense), net		 0.66 0.89 0.81 0.65 0.54 0.55 0.25 0.19 0.13 0.16 1.02
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 0.00 0.00 0.00 - -0.01 0.28 -0.36 -0.05 0.01
Basic Earnings per Share		 ($0.33) ($0.17) ($0.27) ($0.33) ($0.44) ($0.34) ($0.21) ($0.15) ($0.13) ($0.10) ($0.16)
Weighted Average Basic Shares Outstanding		 28.88M 28.66M 29.47M 30.05M 30.27M 31.73M 61.47M 66.18M 67.31M 65.95M 69.59M
Diluted Earnings per Share		 ($0.33) ($0.17) ($0.27) ($0.33) ($0.44) ($0.34) ($0.21) ($0.15) ($0.13) ($0.10) ($0.16)
Weighted Average Diluted Shares Outstanding		 28.88M 28.66M 29.47M 30.05M 30.27M 31.73M 61.47M 66.18M 67.31M 65.95M 69.59M
Weighted Average Basic & Diluted Shares Outstanding		 28.93M 29.76M 30.00M 30.30M 30.35M 65.81M 65.82M 66.12M 68.49M 69.28M 69.59M

Annual Cash Flow Statements for Neuronetics

This table details how cash moves in and out of Neuronetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.97 12 75 -29 -27 45 -24 -11 -40 15
Net Cash From Operating Activities		 -8.54 -11 -21 -30 -28 -28 -31 -32 -31 -20
Net Cash From Continuing Operating Activities		 -8.54 -11 -21 -30 -28 -28 -31 -32 -31 -20
Net Income / (Loss) Continuing Operations		 -11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Consolidated Net Income / (Loss)		 -11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Depreciation Expense		 0.67 0.60 0.88 1.07 0.94 1.06 1.65 2.01 2.07 3.47
Amortization Expense		 0.39 0.72 0.84 0.75 1.19 0.72 0.71 0.63 0.77 0.82
Non-Cash Adjustments To Reconcile Net Income		 0.28 0.44 3.37 -3.42 4.43 7.23 10 11 18 7.86
Changes in Operating Assets and Liabilities, net		 1.35 3.16 -1.58 0.17 -7.50 -5.80 -6.23 -15 -7.81 6.61
Net Cash From Investing Activities		 -0.32 -0.59 -1.01 -0.81 -0.73 -9.84 6.73 -1.32 -2.41 -0.80
Net Cash From Continuing Investing Activities		 -0.32 -0.59 -1.01 -0.81 -0.73 -9.84 6.73 -1.32 -2.41 -0.80
Purchase of Property, Plant & Equipment		 -0.32 -0.59 -1.01 -0.81 -0.73 -2.35 -3.27 -2.37 -1.47 -0.80
Acquisitions		 - - - - - - 0.00 0.00 -2.55 0.00
Other Investing Activities, net		 - - - 0.00 0.00 -7.49 10 1.05 1.61 0.00
Net Cash From Financing Activities		 4.90 24 97 2.42 2.37 83 0.21 23 -6.81 36
Net Cash From Continuing Financing Activities		 4.90 24 97 2.42 2.37 83 0.21 23 -6.81 36
Repayment of Debt		 -0.17 -1.02 0.00 0.00 -40 0.00 -0.09 -2.30 -67 -0.38
Repurchase of Common Equity		 - - -3.46 0.00 0.00 -0.40 - 0.00 0.00 -2.20
Payment of Dividends		 - - - - - - - 0.00 0.00 -0.09
Issuance of Debt		 5.00 10 0.00 0.00 41 0.00 0.00 25 57 10
Issuance of Common Equity		 - - 100 0.00 0.00 81 0.00 0.00 2.52 29
Other Financing Activities, net		 0.07 0.04 0.50 2.42 0.69 2.44 0.30 0.00 0.00 -0.49
Cash Interest Paid		 1.41 2.04 2.79 2.95 3.89 3.30 3.54 4.79 6.51 7.59

Quarterly Cash Flow Statements for Neuronetics

This table details how cash moves in and out of Neuronetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -10 24 -12 -5.09 -22 -1.41 1.77 -3.76 17 -0.34 -15
Net Cash From Operating Activities		 -10 2.13 -12 -4.97 -5.42 -8.60 -17 -3.50 -0.79 0.91 -9.42
Net Cash From Continuing Operating Activities		 -10 2.13 -12 -4.97 -5.42 -8.60 -17 -3.50 -0.79 0.91 -9.42
Net Income / (Loss) Continuing Operations		 -9.39 -5.38 -7.87 -9.83 -13 -13 -13 -9.84 -9.40 -7.21 -11
Consolidated Net Income / (Loss)		 -9.39 -5.38 -7.87 -9.83 -13 -13 -13 -9.84 -9.40 -7.21 -11
Depreciation Expense		 0.50 0.50 0.56 0.56 0.51 0.45 0.91 0.90 0.89 0.77 0.75
Amortization Expense		 0.14 0.17 0.16 0.31 0.11 0.19 0.19 0.20 0.21 0.22 0.26
Non-Cash Adjustments To Reconcile Net Income		 4.66 1.75 2.06 2.31 6.76 4.70 1.46 2.72 2.04 1.64 2.15
Changes in Operating Assets and Liabilities, net		 -6.03 5.09 -6.92 1.69 0.55 -1.25 -6.87 2.51 5.48 5.48 -1.79
Net Cash From Investing Activities		 0.07 -0.56 0.07 -0.12 0.01 -2.38 -0.22 -0.25 -0.11 -0.22 -0.17
Net Cash From Continuing Investing Activities		 0.07 -0.56 0.07 -0.12 0.01 -2.38 -0.22 -0.25 -0.11 -0.22 -0.17
Purchase of Property, Plant & Equipment		 -0.55 -0.88 -0.38 -0.62 -0.39 -0.09 -0.22 -0.25 -0.11 -0.22 -0.20
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.03
Net Cash From Financing Activities		 - 22 0.00 - -16 9.56 19 0.00 18 -1.03 -5.58
Net Cash From Continuing Financing Activities		 - 22 0.00 - -16 9.56 19 0.00 18 -1.03 -5.58
Repayment of Debt		 - -0.24 - - - -0.44 0.00 - - -0.30 -5.25
Repurchase of Common Equity		 - - 0.00 - - - -1.73 - -0.34 -0.14 0.00
Payment of Dividends		 - - - - - - 0.00 - - - -0.08
Issuance of Common Equity		 - - 0.00 - 1.92 0.61 21 - 8.31 - 0.00
Other Financing Activities, net		 - 0.00 0.00 - 0.00 - 0.01 0.00 0.00 -0.50 -0.25
Cash Interest Paid		 1.05 1.67 1.67 1.66 1.62 1.57 1.73 1.76 1.99 2.12 2.01

Annual Balance Sheets for Neuronetics

This table presents Neuronetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 39 117 100 79 141 117 116 141 142
Total Current Assets		 37 114 88 65 115 99 94 58 62
Cash & Equivalents		 29 105 76 49 94 70 60 18 28
Restricted Cash		 - - - - - - 0.00 1.00 6.00
Short-Term Investments		 - - 0.88 1.89 2.20 1.54 0.91 0.21 0.23
Note & Lease Receivable		 - - - - 0.07 0.23 2.06 0.93 0.42
Accounts Receivable		 4.27 5.62 6.57 7.17 7.71 14 16 23 16
Inventories, net		 2.47 2.43 2.78 3.72 6.56 8.90 8.09 4.25 4.33
Prepaid Expenses		 1.12 1.84 2.52 3.28 4.65 4.17 7.28 9.92 5.97
Plant, Property, & Equipment, net		 1.36 1.38 1.11 0.73 1.22 1.99 2.01 6.24 4.47
Total Noncurrent Assets		 0.57 1.17 11 13 25 16 20 77 76
Long-Term Investments		 - - 1.73 2.33 1.70 1.22 0.66 0.09 0.10
Noncurrent Note & Lease Receivables		 - - - - 10 0.36 3.80 0.30 0.15
Goodwill		 - - - - - - 0.00 19 24
Intangible Assets		 - - - - - - 0.00 20 18
Other Noncurrent Operating Assets		 0.57 1.17 8.88 11 13 15 16 38 34
Total Liabilities & Shareholders' Equity		 39 117 100 79 141 117 116 141 142
Total Liabilities		 44 46 52 53 56 60 82 109 115
Total Current Liabilities		 12 14 28 14 16 33 20 31 31
Short-Term Debt		 - - 11 - 0.00 13 0.00 1.00 0.50
Accounts Payable		 2.51 3.76 4.63 3.75 4.30 2.43 4.75 11 11
Accrued Expenses		 7.51 7.55 9.03 7.32 8.23 15 13 13 12
Current Deferred Revenue		 1.97 2.26 2.23 2.02 2.50 1.98 1.62 0.97 0.75
Other Current Liabilities		 - - 0.56 0.59 0.67 0.82 0.85 5.40 6.21
Total Noncurrent Liabilities		 32 32 25 39 40 27 62 78 85
Long-Term Debt		 30 30 20 35 35 23 59 55 66
Noncurrent Deferred Revenue		 2.43 2.03 2.11 1.74 1.47 0.83 0.20 0.00 0.05
Other Noncurrent Operating Liabilities		 0.48 - 2.62 3.12 3.54 2.97 2.35 23 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -193 71 48 25 85 57 34 32 26
Total Preferred & Common Equity		 -193 71 48 25 85 57 34 28 22
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -193 71 48 25 85 57 34 28 22
Common Stock		 4.29 292 298 303 394 403 410 447 481
Retained Earnings		 -197 -221 -250 -278 -309 -346 -376 -420 -459
Noncontrolling Interest		 - - - - - - 0.00 4.09 3.86

Quarterly Balance Sheets for Neuronetics

This table presents Neuronetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 93 104 97 74 142 135 145 125
Total Current Assets		 71 82 76 53 61 56 65 47
Cash & Equivalents		 36 48 43 21 20 11 28 13
Restricted Cash		 - - - - 1.00 6.50 6.50 5.75
Short-Term Investments		 0.97 0.82 0.69 0.57 0.20 0.18 0.18 0.26
Note & Lease Receivable		 1.85 2.12 2.36 2.48 0.70 0.53 0.49 0.40
Accounts Receivable		 15 18 17 17 26 26 19 16
Inventories, net		 9.74 6.69 6.14 4.96 4.07 4.94 4.32 4.72
Prepaid Expenses		 7.59 7.00 6.53 7.76 8.28 6.91 6.73 7.03
Plant, Property, & Equipment, net		 2.07 1.85 1.73 1.64 5.85 5.32 4.94 3.87
Total Noncurrent Assets		 20 20 20 19 75 73 76 74
Long-Term Investments		 0.70 0.52 0.27 0.14 0.07 0.10 0.09 0.11
Noncurrent Note & Lease Receivables		 4.19 3.66 3.15 2.88 0.32 0.33 0.22 0.09
Goodwill		 - - - - 19 19 23 24
Intangible Assets		 - - - - 19 19 19 18
Other Noncurrent Operating Assets		 15 16 16 16 37 35 34 33
Total Liabilities & Shareholders' Equity		 93 104 97 74 142 135 145 125
Total Liabilities		 55 76 77 65 102 103 114 108
Total Current Liabilities		 15 14 29 17 25 28 29 28
Short-Term Debt		 0.00 - 14 - 1.00 1.00 1.00 0.25
Accounts Payable		 2.82 2.98 4.10 3.30 8.48 9.73 12 11
Accrued Expenses		 10 9.05 9.24 11 9.31 11 9.65 9.60
Current Deferred Revenue		 1.64 1.62 1.45 1.31 0.79 0.89 0.75 0.83
Other Current Liabilities		 0.84 0.85 0.86 0.86 5.27 5.60 5.96 6.17
Total Noncurrent Liabilities		 40 62 48 48 78 75 85 80
Long-Term Debt		 37 59 46 46 55 56 66 61
Noncurrent Deferred Revenue		 0.35 0.04 0.02 0.00 0.00 0.00 0.00 0.06
Other Noncurrent Operating Liabilities		 2.51 2.18 2.01 1.83 22 20 19 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 38 28 19 9.38 40 32 31 17
Total Preferred & Common Equity		 38 28 19 9.38 35 27 27 13
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 38 28 19 9.38 35 27 27 13
Common Stock		 409 412 413 417 468 470 479 483
Retained Earnings		 -371 -384 -394 -407 -432 -443 -452 -470
Noncontrolling Interest		 - - - - 4.08 4.36 4.00 3.80

Annual Metrics And Ratios for Neuronetics

This table displays calculated financial ratios and metrics derived from Neuronetics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 17,579,491.00 18,632,268.00 18,975,322.00 26,367,959.00 27,221,490.00 28,933,132.00 - 68,485,922.00
DEI Adjusted Shares Outstanding		 0.00 0.00 17,579,491.00 18,632,268.00 18,975,322.00 26,367,959.00 27,221,490.00 28,933,132.00 - 68,485,922.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.37 -1.56 -1.45 -1.18 -1.37 -1.04 - -0.57
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 18.13% 30.53% 18.72% -21.41% 12.32% 17.89% 9.42% 4.96% 99.17%
EBITDA Growth		 0.00% -43.17% -56.61% -25.97% 15.58% -27.80% -20.28% 27.58% -31.84% 9.39%
EBIT Growth		 0.00% -40.98% -54.02% -24.25% 13.22% -23.48% -21.10% 24.74% -29.27% 4.04%
NOPAT Growth		 0.00% -45.74% -45.75% -35.78% 17.16% -23.56% -27.38% 12.98% -13.12% 9.05%
Net Income Growth		 0.00% -42.95% -50.05% -20.53% 5.48% -13.62% -19.13% 18.76% -44.84% 10.50%
EPS Growth		 0.00% -12.20% 96.88% 41.26% 7.59% 16.44% -13.11% 23.91% -31.43% 57.25%
Operating Cash Flow Growth		 0.00% -30.48% -84.77% -48.04% 6.86% 1.43% -9.85% -4.23% 3.25% 34.27%
Free Cash Flow Firm Growth		 0.00% 0.00% -258.59% -43.13% 3.56% -59.25% 36.79% -53.08% -78.51% 80.23%
Invested Capital Growth		 0.00% 0.00% 38.40% 121.68% 917.30% 223.93% -11.39% 61.85% 111.60% -14.82%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 2.82% -3.48% -1.00% 5.12% 3.06% 3.00% 14.85%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -6.11% 15.99% -16.95% -0.76% 13.39% -34.18% 19.47%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -6.04% 15.39% -16.89% -1.56% 12.52% -30.01% 16.42%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -4.98% 16.09% -18.22% -2.38% 9.75% -25.59% 16.97%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -5.11% 12.43% -14.62% -1.79% 8.80% -20.05% 12.27%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -103.07% 12.57% -10.91% 0.72% 11.02% -14.05% 28.92%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -14.10% -15.66% 14.20% -11.21% 4.43% 14.04% -52.94% 31.81%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 12.14% -9.64% 3.00% 14.49% -280.98% 78.75%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -39.96% -6.50% -1.73% -7.64% -13.54% 101.75% -8.22%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 80.65% 76.18% 76.42% 75.44% 76.54% 78.93% 76.26% 72.47% 72.32% 48.48%
EBITDA Margin		 -24.35% -29.51% -35.41% -37.57% -40.36% -45.92% -46.85% -31.01% -38.95% -17.72%
Operating Margin		 -27.28% -33.66% -37.58% -42.98% -45.30% -49.83% -53.85% -42.82% -46.15% -21.08%
EBIT Margin		 -27.46% -32.77% -38.67% -40.47% -44.69% -49.13% -50.47% -34.71% -42.75% -20.60%
Profit (Net Income) Margin		 -32.82% -39.72% -45.66% -46.35% -55.75% -56.39% -56.99% -42.31% -58.39% -26.24%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 119.52% 121.19% 118.07% 114.53% 124.75% 114.79% 112.92% 121.90% 136.59% 127.39%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -409.88% -131.20% -115.97% -82.03% -48.18% -34.85%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -373.86% -101.92% -90.76% -37.02% -161.61% -85.05%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 335.02% 74.83% 63.72% 15.87% -84.35% -100.01%
Return on Equity (ROE)		 0.00% 291.13% -73.55% -48.86% -74.86% -56.37% -52.25% -66.17% -132.53% -134.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -3,325.37% -574.08% -236.85% -103.89% -129.27% -119.81% -18.84%
Operating Return on Assets (OROA)		 0.00% -34.03% -26.17% -23.35% -24.61% -24.72% -25.50% -21.28% -24.94% -21.75%
Return on Assets (ROA)		 0.00% -41.24% -30.90% -26.75% -30.70% -28.37% -28.79% -25.95% -34.06% -27.71%
Return on Common Equity (ROCE)		 0.00% 10,168.19% 136.50% -48.86% -74.86% -56.37% -52.25% -66.17% -124.31% -116.37%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 8.34% -33.92% -60.70% -107.69% -36.62% -65.12% 0.00% -157.83% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.54 -9.53 -14 -19 -16 -19 -25 -21 -24 -22
NOPAT Margin		 -19.10% -23.56% -26.31% -30.09% -31.71% -34.88% -37.69% -29.98% -32.31% -14.75%
Net Nonoperating Expense Percent (NNEP)		 0.00% 3,194.82% -27.69% -16.80% -36.02% -29.29% -25.20% -45.01% 113.43% 50.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -26.42% -22.88% -27.51% -23.78%
Cost of Revenue to Revenue		 19.35% 23.82% 23.58% 24.56% 23.46% 21.07% 23.74% 27.53% 27.68% 51.52%
SG&A Expenses to Revenue		 20.23% 21.20% 25.90% 27.86% 37.03% 46.20% 39.13% 35.64% 40.49% 33.32%
R&D to Revenue		 24.02% 19.63% 15.60% 21.94% 18.68% 14.32% 14.32% 13.34% 17.05% 4.41%
Operating Expenses to Revenue		 107.93% 109.83% 114.00% 118.42% 121.84% 128.77% 130.10% 115.29% 118.47% 69.55%
Earnings before Interest and Taxes (EBIT)		 -9.40 -13 -20 -25 -22 -27 -33 -25 -32 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.34 -12 -19 -24 -20 -25 -31 -22 -29 -26
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 4.79 1.75 8.27 1.38 3.28 2.45 1.76 4.22
Price to Tangible Book Value (P/TBV)		 0.00 0.00 4.79 1.75 8.27 1.38 3.28 2.45 0.00 0.00
Price to Revenue (P/Rev)		 2.73 2.31 6.45 1.34 4.28 2.13 2.87 1.18 0.65 0.63
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 53.50 27.71 2.44 7.53 2.54 1.31 2.24
Enterprise Value to Revenue (EV/Rev)		 0.00 6.95 5.04 0.58 3.90 0.99 2.30 1.15 1.19 0.87
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 -5.36 0.43 0.65 1.36 0.41 0.63 1.73 1.77 2.53
Long-Term Debt to Equity		 0.00 -5.36 0.43 0.42 1.36 0.41 0.40 1.73 1.73 2.51
Financial Leverage		 0.00 -0.07 -1.13 -1.02 -0.90 -0.73 -0.70 -0.43 0.52 1.18
Leverage Ratio		 0.00 -7.06 2.38 1.83 2.44 1.99 1.81 2.55 3.89 4.87
Compound Leverage Factor		 0.00 -8.56 2.81 2.09 3.04 2.28 2.05 3.11 5.31 6.20
Debt to Total Capital		 0.00% 122.95% 29.96% 39.43% 57.59% 29.32% 38.65% 63.42% 63.84% 71.65%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 14.24% 0.00% 0.00% 14.11% 0.00% 1.14% 0.54%
Long-Term Debt to Total Capital		 0.00% 122.95% 29.96% 25.19% 57.59% 29.32% 24.54% 63.42% 62.71% 71.11%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 778.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.65% 4.17%
Common Equity to Total Capital		 0.00% -801.38% 70.04% 60.57% 42.41% 70.68% 61.35% 36.58% 31.50% 24.18%
Debt to EBITDA		 0.00 -2.48 -1.63 -1.32 -1.74 -1.39 -1.18 -2.68 -1.93 -2.51
Net Debt to EBITDA		 0.00 -0.03 3.97 2.00 0.93 2.47 1.22 0.09 -1.25 -1.21
Long-Term Debt to EBITDA		 0.00 -2.48 -1.63 -0.85 -1.74 -1.39 -0.75 -2.68 -1.89 -2.49
Debt to NOPAT		 0.00 -3.10 -2.19 -1.65 -2.22 -1.83 -1.46 -2.77 -2.32 -3.01
Net Debt to NOPAT		 0.00 -0.04 5.34 2.50 1.19 3.25 1.51 0.09 -1.50 -1.45
Long-Term Debt to NOPAT		 0.00 -3.10 -2.19 -1.06 -2.22 -1.83 -0.93 -2.77 -2.28 -2.99
Altman Z-Score		 0.00 -5.13 2.70 -2.02 -2.07 -1.20 -1.97 -3.25 -3.89 -3.45
Noncontrolling Interest Sharing Ratio		 0.00% -3,392.60% 285.59% 0.00% 0.00% 0.00% 0.00% 0.00% 6.20% 13.71%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 3.09 8.44 3.19 4.75 7.34 2.98 4.73 1.86 2.02
Quick Ratio		 0.00 2.79 8.13 3.00 4.24 6.63 2.58 3.96 1.37 1.48
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -4.42 -16 -23 -22 -35 -22 -34 -60 -12
Operating Cash Flow to CapEx		 -2,636.11% -1,876.09% -2,036.70% -3,749.32% -3,889.04% -1,189.25% -940.32% -1,352.39% -2,114.39% -2,543.57%
Free Cash Flow to Firm to Interest Expense		 0.00 -1.57 -4.30 -6.15 -4.02 -8.67 -5.18 -6.21 -5.14 -1.41
Operating Cash Flow to Interest Expense		 -4.65 -3.97 -5.58 -8.27 -5.21 -6.96 -7.23 -5.91 -2.65 -2.42
Operating Cash Flow Less CapEx to Interest Expense		 -4.83 -4.18 -5.86 -8.49 -5.35 -7.55 -8.00 -6.34 -2.77 -2.52
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 1.04 0.68 0.58 0.55 0.50 0.51 0.61 0.58 1.06
Accounts Receivable Turnover		 0.00 9.48 10.68 10.28 7.17 7.44 6.12 4.86 3.83 7.49
Inventory Turnover		 0.00 3.90 5.08 5.91 3.56 2.27 2.00 2.31 3.36 17.92
Fixed Asset Turnover		 0.00 29.75 38.56 50.43 53.61 56.73 40.61 35.67 18.15 27.86
Accounts Payable Turnover		 0.00 3.83 3.97 3.67 2.76 2.90 4.60 5.47 2.62 7.05
Days Sales Outstanding (DSO)		 0.00 38.52 34.19 35.50 50.90 49.07 59.61 75.13 95.37 48.73
Days Inventory Outstanding (DIO)		 0.00 93.52 71.84 61.75 102.59 161.04 182.25 157.87 108.65 20.36
Days Payable Outstanding (DPO)		 0.00 95.23 91.92 99.39 132.27 126.04 79.35 66.75 139.36 51.81
Cash Conversion Cycle (CCC)		 0.00 36.81 14.12 -2.14 21.22 84.07 162.51 166.25 64.66 17.28
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -5.11 -3.15 0.68 6.94 22 20 32 68 58
Invested Capital Turnover		 0.00 -15.83 -12.79 -50.86 12.92 3.76 3.08 2.74 1.49 2.36
Increase / (Decrease) in Invested Capital		 0.00 -5.11 1.96 3.83 6.26 16 -2.56 12 36 -10
Enterprise Value (EV)		 0.00 281 266 36 192 55 150 82 89 130
Market Capitalization		 94 94 340 84 211 118 187 84 49 95
Book Value per Share		 $0.00 ($1,035.76) $4.04 $2.57 $1.34 $3.23 $2.10 $1.18 $0.91 $0.33
Tangible Book Value per Share		 $0.00 ($1,035.76) $4.04 $2.57 $1.34 $3.23 $2.10 $1.18 ($0.35) ($0.28)
Total Capital		 0.00 24 101 79 60 121 93 93 88 93
Total Debt		 0.00 30 30 31 35 35 36 59 56 66
Total Long-Term Debt		 0.00 30 30 20 35 35 23 59 55 66
Net Debt		 0.00 0.41 -74 -47 -19 -63 -37 -1.96 36 32
Capital Expenditures (CapEx)		 0.32 0.59 1.01 0.81 0.73 2.35 3.27 2.37 1.47 0.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.14 -3.67 -4.58 0.49 3.29 6.82 13 8.19 -2.83
Debt-free Net Working Capital (DFNWC)		 0.00 25 101 72 51 100 79 74 28 32
Net Working Capital (NWC)		 0.00 25 101 61 51 100 66 74 27 31
Net Nonoperating Expense (NNE)		 4.70 6.53 10 10 12 12 13 8.80 20 17
Net Nonoperating Obligations (NNO)		 0.00 0.41 -74 -47 -19 -63 -37 -1.96 36 32
Total Depreciation and Amortization (D&A)		 1.06 1.32 1.72 1.82 2.13 1.78 2.36 2.64 2.84 4.29
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -10.23% -6.95% -7.31% 0.99% 5.95% 10.45% 18.78% 10.94% -1.90%
Debt-free Net Working Capital to Revenue		 0.00% 61.86% 191.21% 114.93% 104.24% 180.12% 120.69% 103.69% 37.20% 21.14%
Net Working Capital to Revenue		 0.00% 61.86% 191.21% 96.97% 104.24% 180.12% 100.56% 103.69% 35.86% 20.80%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($76.95) ($86.34) ($2.69) ($1.58) $0.00 ($1.22) ($1.38) ($1.05) ($1.38) ($0.59)
Adjusted Weighted Average Basic Shares Outstanding		 146K 186K 18.05M 18.67M 0.00 25.48M 26.90M 28.66M 31.73M 65.95M
Adjusted Diluted Earnings per Share		 ($76.95) ($86.34) ($2.69) ($1.58) $0.00 ($1.22) ($1.38) ($1.05) ($1.38) ($0.59)
Adjusted Weighted Average Diluted Shares Outstanding		 146K 186K 18.05M 18.67M 0.00 25.48M 26.90M 28.66M 31.73M 65.95M
Adjusted Basic & Diluted Earnings per Share		 ($76.95) ($86.34) ($2.69) ($1.58) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 146K 186K 8.95M 18.38M 0.00 26.63M 28.36M 29.76M 65.81M 69.28M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.54 -9.53 -14 -19 -16 -19 -25 -21 -24 -22
Normalized NOPAT Margin		 -19.10% -23.56% -26.31% -30.09% -31.71% -34.88% -37.69% -29.98% -32.31% -14.75%
Pre Tax Income Margin		 -32.82% -39.72% -45.66% -46.35% -55.75% -56.39% -56.99% -42.31% -58.39% -26.24%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -5.12 -4.72 -5.53 -6.88 -4.04 -6.76 -7.74 -4.57 -2.73 -3.65
NOPAT to Interest Expense		 -3.56 -3.39 -3.76 -5.12 -2.87 -4.80 -5.78 -3.94 -2.07 -2.62
EBIT Less CapEx to Interest Expense		 -5.30 -4.93 -5.81 -7.10 -4.18 -7.35 -8.51 -5.00 -2.86 -3.75
NOPAT Less CapEx to Interest Expense		 -3.74 -3.60 -4.04 -5.34 -3.00 -5.39 -6.55 -4.38 -2.19 -2.71
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.24%
Augmented Payout Ratio		 0.00% 0.00% -14.37% 0.00% 0.00% -1.29% 0.00% 0.00% 0.00% -5.87%

Quarterly Metrics And Ratios for Neuronetics

This table displays calculated financial ratios and metrics derived from Neuronetics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 28,873,388.00 28,933,132.00 29,756,053.00 29,997,563.00 30,295,465.00 - 65,814,512.00 65,820,344.00 66,124,820.00 68,485,922.00 69,276,593.00
DEI Adjusted Shares Outstanding		 28,873,388.00 28,933,132.00 29,756,053.00 29,997,563.00 30,295,465.00 - 65,814,512.00 65,820,344.00 66,124,820.00 68,485,922.00 69,276,593.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.33 -0.19 -0.26 -0.33 -0.44 - -0.19 -0.15 -0.14 -0.10 -0.16
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 8.40% 11.63% 12.08% -6.59% 3.61% 10.73% 83.59% 131.66% 101.28% 85.73% 7.75%
EBITDA Growth		 -26.42% 54.49% 37.80% -122.84% 13.20% -260.06% -81.51% 3.09% 7.21% 62.12% 27.86%
EBIT Growth		 -25.34% 50.07% 34.75% -109.05% 12.40% -209.11% -78.06% -0.20% -0.08% 55.25% 25.93%
NOPAT Growth		 -19.01% 42.70% 30.77% -15.76% 12.88% -159.07% -60.58% 5.28% 5.27% 56.03% 18.33%
Net Income Growth		 -23.42% 35.14% 25.16% -100.61% -42.06% -135.84% -61.17% -0.07% 29.53% 43.17% 15.04%
EPS Growth		 -17.86% 43.33% 28.95% -94.12% -33.33% -100.00% 22.22% 54.55% 70.45% 70.59% 23.81%
Operating Cash Flow Growth		 -55.59% 168.81% 21.02% 43.75% 46.49% -503.00% -41.43% 29.48% 85.51% 110.56% 44.56%
Free Cash Flow Firm Growth		 -460.79% -441.22% -137.84% 29.91% 91.17% -185.42% -183.43% -464.90% -1,687.24% 114.95% 119.97%
Invested Capital Growth		 72.89% 61.85% 39.34% 3.48% -9.32% 111.60% 95.53% 97.75% 87.23% -14.82% -20.30%
Revenue Q/Q Growth		 1.56% 13.59% -14.26% -5.55% 12.64% 21.39% 42.16% 19.18% -2.13% 12.01% -17.53%
EBITDA Q/Q Growth		 -141.47% 62.26% -86.42% -31.17% 5.94% -56.55% 6.03% 29.97% 9.94% 36.08% -78.96%
EBIT Q/Q Growth		 -118.45% 56.94% -71.11% -29.88% 8.47% -51.95% 1.44% 26.91% 8.58% 32.06% -63.15%
NOPAT Q/Q Growth		 -20.71% 50.10% -54.94% -24.03% 9.16% -48.41% 3.97% 26.84% 9.15% 31.12% -78.37%
Net Income Q/Q Growth		 -91.61% 42.74% -46.42% -24.88% -35.69% 4.95% -0.06% 22.46% 4.45% 23.35% -49.60%
EPS Q/Q Growth		 -94.12% 48.48% -58.82% -22.22% -33.33% 22.73% 38.24% 28.57% 13.33% 23.08% -60.00%
Operating Cash Flow Q/Q Growth		 -14.60% 121.07% -663.29% 58.64% -9.02% -58.69% -97.69% 79.38% 77.60% 215.67% -1,137.56%
Free Cash Flow Firm Q/Q Growth		 -114.95% 29.69% -0.81% 53.99% 72.91% -2,171.88% -0.11% 8.30% 14.31% 119.01% 33.72%
Invested Capital Q/Q Growth		 8.51% -13.54% 18.01% -6.54% -4.91% 101.75% 9.05% -5.48% -9.97% -8.22% 2.05%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 65.78% 77.64% 75.15% 74.04% 75.56% 66.21% 49.22% 46.60% 45.87% 51.95% 46.89%
EBITDA Margin		 -42.33% -14.06% -30.58% -42.47% -35.46% -45.73% -30.23% -17.77% -16.35% -9.33% -20.24%
Operating Margin		 -49.60% -21.79% -39.38% -51.71% -41.71% -50.99% -34.45% -21.15% -19.63% -12.07% -26.11%
EBIT Margin		 -45.89% -17.40% -34.72% -47.74% -38.80% -48.57% -33.67% -20.65% -19.29% -11.70% -23.15%
Profit (Net Income) Margin		 -52.51% -26.47% -45.20% -59.77% -72.00% -56.38% -39.68% -25.82% -25.21% -17.25% -31.29%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 114.43% 152.15% 130.20% 125.18% 185.58% 116.08% 117.85% 125.02% 130.66% 147.42% 135.17%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -81.71% -41.75% -61.79% -74.64% -59.73% -53.23% -38.37% -31.07% -36.76% -19.96% -41.47%
ROIC Less NNEP Spread (ROIC-NNEP)		 -66.60% -30.10% -4.20% -228.49% -126.49% -80.25% -60.40% -46.35% -51.93% -30.73% -53.11%
Return on Net Nonoperating Assets (RNNOA)		 27.77% 12.90% 0.59% -17.75% -63.51% -41.88% -40.65% -50.05% -71.84% -36.14% -72.31%
Return on Equity (ROE)		 -53.94% -28.85% -61.20% -92.39% -123.23% -95.12% -79.03% -81.13% -108.59% -56.10% -113.78%
Cash Return on Invested Capital (CROIC)		 -133.97% -129.27% -91.82% -60.83% -44.43% -119.81% -112.87% -116.28% -115.33% -18.84% -8.23%
Operating Return on Assets (OROA)		 -29.94% -10.67% -24.51% -34.89% -33.76% -28.33% -24.51% -19.83% -22.82% -12.36% -26.25%
Return on Assets (ROA)		 -34.26% -16.23% -31.92% -43.68% -62.65% -32.89% -28.88% -24.79% -29.82% -18.22% -35.48%
Return on Common Equity (ROCE)		 -53.94% -28.85% -61.20% -92.39% -123.23% -89.22% -74.23% -74.18% -97.92% -48.41% -97.95%
Return on Equity Simple (ROE_SIMPLE)		 -87.25% 0.00% -99.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.21 -3.10 -4.80 -5.95 -5.41 -8.03 -7.71 -5.64 -5.12 -3.53 -6.30
NOPAT Margin		 -34.72% -15.26% -27.57% -36.20% -29.19% -35.69% -24.11% -14.80% -13.74% -8.45% -18.28%
Net Nonoperating Expense Percent (NNEP)		 -15.12% -11.65% -57.59% 153.85% 66.77% 27.02% 22.02% 15.28% 15.18% 10.77% 11.64%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.32% -5.51% -7.52% -9.77% -9.13% -8.04% -6.41% -5.23% -3.81% -8.01%
Cost of Revenue to Revenue		 34.22% 22.36% 24.86% 25.96% 24.44% 33.79% 50.78% 53.40% 54.13% 48.05% 53.11%
SG&A Expenses to Revenue		 35.45% 30.89% 34.20% 37.37% 40.13% 47.93% 41.09% 31.88% 29.70% 31.93% 37.87%
R&D to Revenue		 12.05% 10.86% 13.49% 13.59% 13.04% 25.66% 5.05% 4.72% 4.03% 3.99% 3.96%
Operating Expenses to Revenue		 115.38% 99.43% 114.53% 125.75% 117.26% 117.20% 83.67% 67.74% 65.50% 64.02% 72.99%
Earnings before Interest and Taxes (EBIT)		 -8.21 -3.53 -6.05 -7.85 -7.19 -11 -11 -7.87 -7.20 -4.89 -7.98
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.57 -2.86 -5.33 -6.99 -6.57 -10 -9.67 -6.77 -6.10 -3.90 -6.97
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.03 2.45 5.12 2.79 2.45 1.76 6.83 8.46 6.60 4.22 7.57
Price to Tangible Book Value (P/TBV)		 1.03 2.45 5.12 2.79 2.45 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.56 1.18 1.93 0.75 0.32 0.65 2.71 2.07 1.39 0.63 0.66
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.03 2.54 4.00 1.97 1.40 1.31 3.78 3.88 3.42 2.24 2.47
Enterprise Value to Revenue (EV/Rev)		 0.55 1.15 2.08 0.97 0.65 1.19 3.14 2.46 1.67 0.87 0.97
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.97 1.73 2.15 3.08 4.90 1.77 1.43 1.79 2.13 2.53 3.61
Long-Term Debt to Equity		 0.97 1.73 2.15 2.38 4.90 1.73 1.40 1.76 2.09 2.51 3.59
Financial Leverage		 -0.42 -0.43 -0.14 0.08 0.50 0.52 0.67 1.08 1.38 1.18 1.36
Leverage Ratio		 2.10 2.55 2.73 3.04 3.53 3.89 3.66 4.55 5.39 4.87 4.73
Compound Leverage Factor		 2.41 3.88 3.55 3.81 6.55 4.52 4.31 5.69 7.04 7.17 6.39
Debt to Total Capital		 49.27% 63.42% 68.25% 75.51% 83.06% 63.84% 58.77% 64.22% 68.01% 71.65% 78.30%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 17.20% 0.00% 1.14% 1.04% 1.14% 1.02% 0.54% 0.32%
Long-Term Debt to Total Capital		 49.27% 63.42% 68.25% 58.31% 83.06% 62.71% 57.72% 63.08% 66.99% 71.11% 77.98%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 4.65% 4.25% 4.95% 4.08% 4.17% 4.83%
Common Equity to Total Capital		 50.73% 36.58% 31.75% 24.49% 16.94% 31.50% 36.98% 30.83% 27.91% 24.18% 16.88%
Debt to EBITDA		 -1.44 -2.68 -3.15 -2.63 -2.12 -1.93 -1.68 -1.70 -2.03 -2.51 -2.59
Net Debt to EBITDA		 0.03 0.09 -0.55 -0.71 -1.12 -1.25 -1.04 -1.17 -0.97 -1.21 -1.78
Long-Term Debt to EBITDA		 -1.44 -2.68 -3.15 -2.03 -2.12 -1.89 -1.65 -1.67 -2.00 -2.49 -2.58
Debt to NOPAT		 -1.56 -2.77 -3.09 -2.98 -2.39 -2.32 -2.08 -2.11 -2.52 -3.01 -2.99
Net Debt to NOPAT		 0.03 0.09 -0.54 -0.81 -1.27 -1.50 -1.29 -1.45 -1.20 -1.45 -2.05
Long-Term Debt to NOPAT		 -1.56 -2.77 -3.09 -2.30 -2.39 -2.28 -2.04 -2.07 -2.48 -2.99 -2.98
Altman Z-Score		 -3.98 -2.65 -2.77 -4.23 -6.22 -3.40 -2.16 -2.38 -2.37 -2.84 -3.51
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 6.20% 6.07% 8.57% 9.83% 13.71% 13.91%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.63 4.73 5.65 2.58 3.16 1.86 2.44 2.02 2.24 2.02 1.67
Quick Ratio		 3.50 3.96 4.70 2.15 2.41 1.37 1.90 1.36 1.64 1.48 1.05
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -22 -15 -16 -7.15 -1.94 -44 -44 -40 -35 6.58 8.80
Operating Cash Flow to CapEx		 -1,834.06% 242.66% -3,204.00% -806.66% -1,403.37% -9,658.43% -7,759.36% -1,390.48% -688.60% 420.37% -5,477.33%
Free Cash Flow to Firm to Interest Expense		 -18.52 -8.36 -8.51 -3.61 -0.31 -25.04 -22.92 -20.51 -15.69 2.84 3.14
Operating Cash Flow to Interest Expense		 -8.55 1.16 -6.58 -2.51 -0.88 -4.89 -8.84 -1.78 -0.36 0.39 -3.36
Operating Cash Flow Less CapEx to Interest Expense		 -9.02 0.68 -6.79 -2.82 -0.94 -4.94 -8.96 -1.91 -0.41 0.30 -3.42
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.65 0.61 0.71 0.73 0.87 0.58 0.73 0.96 1.18 1.06 1.13
Accounts Receivable Turnover		 5.13 4.86 5.43 4.76 4.57 3.83 4.09 5.14 7.31 7.49 7.22
Inventory Turnover		 2.13 2.31 2.50 2.57 2.40 3.36 6.06 8.79 13.87 17.92 17.97
Fixed Asset Turnover		 33.17 35.67 38.17 37.57 39.25 18.15 23.25 31.51 39.50 27.86 31.20
Accounts Payable Turnover		 7.54 5.47 4.99 4.67 5.78 2.62 5.70 7.05 8.66 7.05 7.92
Days Sales Outstanding (DSO)		 71.14 75.13 67.18 76.70 79.94 95.37 89.16 71.06 49.91 48.73 50.55
Days Inventory Outstanding (DIO)		 171.46 157.87 145.76 142.24 151.78 108.65 60.18 41.53 26.31 20.36 20.31
Days Payable Outstanding (DPO)		 48.43 66.75 73.16 78.11 63.17 139.36 64.09 51.80 42.15 51.81 46.06
Cash Conversion Cycle (CCC)		 194.17 166.25 139.78 140.82 168.55 64.66 85.26 60.78 34.07 17.28 24.81
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 37 32 38 36 34 68 74 70 63 58 59
Invested Capital Turnover		 2.35 2.74 2.24 2.06 2.05 1.49 1.59 2.10 2.68 2.36 2.27
Increase / (Decrease) in Invested Capital		 16 12 11 1.20 -3.47 36 36 35 29 -10 -15
Enterprise Value (EV)		 38 82 152 70 47 89 281 273 216 130 146
Market Capitalization		 39 84 142 54 23 49 242 230 181 95 100
Book Value per Share		 $1.31 $1.18 $0.93 $0.65 $0.31 $0.91 $0.54 $0.41 $0.41 $0.33 $0.19
Tangible Book Value per Share		 $1.31 $1.18 $0.93 $0.65 $0.31 ($0.35) ($0.04) ($0.16) ($0.21) ($0.28) ($0.41)
Total Capital		 75 93 87 79 55 88 96 88 98 93 79
Total Debt		 37 59 59 60 46 56 56 57 67 66 62
Total Long-Term Debt		 37 59 59 46 46 55 55 56 66 66 61
Net Debt		 -0.66 -1.96 10 16 24 36 35 39 32 32 42
Capital Expenditures (CapEx)		 0.55 0.88 0.38 0.62 0.39 0.09 0.22 0.25 0.11 0.22 0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 19 13 19 17 15 8.19 15 12 2.30 -2.83 -0.08
Debt-free Net Working Capital (DFNWC)		 56 74 67 60 37 28 37 29 37 32 19
Net Working Capital (NWC)		 56 74 67 46 37 27 36 28 36 31 19
Net Nonoperating Expense (NNE)		 3.18 2.28 3.07 3.88 7.93 4.65 4.98 4.20 4.28 3.68 4.48
Net Nonoperating Obligations (NNO)		 -0.66 -1.96 10 16 24 36 35 39 32 32 42
Total Depreciation and Amortization (D&A)		 0.64 0.68 0.72 0.87 0.62 0.64 1.10 1.10 1.10 0.99 1.00
Debt-free, Cash-free Net Working Capital to Revenue		 27.24% 18.78% 25.70% 22.94% 20.80% 10.94% 17.22% 10.52% 1.77% -1.90% -0.05%
Debt-free Net Working Capital to Revenue		 80.42% 103.69% 92.00% 83.06% 50.28% 37.20% 41.17% 26.40% 28.45% 21.14% 12.62%
Net Working Capital to Revenue		 80.42% 103.69% 92.00% 64.18% 50.28% 35.86% 40.05% 25.50% 27.68% 20.80% 12.46%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.33) ($0.17) ($0.27) ($0.33) ($0.44) ($0.34) ($0.21) ($0.15) ($0.13) ($0.10) ($0.16)
Adjusted Weighted Average Basic Shares Outstanding		 28.88M 28.66M 29.47M 30.05M 30.27M 31.73M 61.47M 66.18M 67.31M 65.95M 69.59M
Adjusted Diluted Earnings per Share		 ($0.33) ($0.17) ($0.27) ($0.33) ($0.44) ($0.34) ($0.21) ($0.15) ($0.13) ($0.10) ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding		 28.88M 28.66M 29.47M 30.05M 30.27M 31.73M 61.47M 66.18M 67.31M 65.95M 69.59M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 28.93M 29.76M 30.00M 30.30M 30.35M 65.81M 65.82M 66.12M 68.49M 69.28M 69.59M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.21 -3.10 -4.80 -5.95 -5.41 -8.03 -7.71 -5.64 -5.12 -3.53 -6.30
Normalized NOPAT Margin		 -34.72% -15.26% -27.57% -36.20% -29.19% -35.69% -24.11% -14.80% -13.74% -8.45% -18.28%
Pre Tax Income Margin		 -52.51% -26.47% -45.20% -59.77% -72.00% -56.38% -39.68% -25.82% -25.21% -17.25% -31.29%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -6.93 -1.92 -3.31 -3.97 -1.17 -6.22 -5.60 -4.00 -3.26 -2.11 -2.84
NOPAT to Interest Expense		 -5.24 -1.68 -2.63 -3.01 -0.88 -4.57 -4.01 -2.86 -2.32 -1.52 -2.24
EBIT Less CapEx to Interest Expense		 -7.40 -2.39 -3.52 -4.28 -1.23 -6.27 -5.72 -4.12 -3.31 -2.20 -2.90
NOPAT Less CapEx to Interest Expense		 -5.71 -2.16 -2.83 -3.32 -0.94 -4.62 -4.13 -2.99 -2.37 -1.62 -2.31
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.24% -0.46%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.57% 0.00% 0.00% -5.87% -1.73%

Financials Breakdown Chart

Key Financial Trends

Neuronetics (NASDAQ: STIM) showed improving revenue trends in Q1 2026, but profitability and cash burn remain major concerns. Revenue rose to $34.5 million in Q1 2026 from $31.0 million a year ago, but the company still posted a net loss of $10.8 million and used $9.4 million in operating cash during the quarter.

On the positive side, top-line growth is visible. Q1 2026 revenue increased about 8% year over year and gross profit improved to $16.2 million, with gross margin near 46.9%, up from roughly 47.8% in Q1 2025 and 73% in the much smaller Q4 2024 base. The company also ended Q1 2026 with $19.2 million of cash, cash equivalents, and short-term investments, plus $5.8 million of restricted cash.

However, the balance sheet and cash flow profile still look stretched. Total liabilities were $108.4 million versus just $13.3 million of common equity, meaning leverage remains high relative to equity. Long-term debt stood at $61.3 million, and the company also reported $5.3 million of debt repayment in Q1 2026. That repayment may help delever over time, but it also adds to the near-term cash burden.

Operating performance remains the key issue. Even with revenue growth, operating expenses were $25.1 million in Q1 2026, leaving an operating loss of $9.0 million. Interest expense of $2.8 million continues to weigh heavily on pre-tax results, and the company reported a pre-tax loss of $10.8 million.

  • Q1 2026 revenue rose to $34.5 million, up from $31.0 million in Q1 2025.
  • Gross profit increased to $16.2 million, showing the business is generating meaningful product margin.
  • Cash, cash equivalents, short-term investments, and restricted cash together provided a liquidity cushion at quarter end.
  • Debt repayment of $5.25 million in Q1 2026 suggests management is working to reduce leverage.
  • Accounts receivable remained elevated at $15.8 million, which is manageable but worth watching alongside sales growth.
  • Noncontrolling interest and other non-operating items make equity and earnings figures a bit harder to compare quarter to quarter.
  • The company posted a net loss of $10.8 million in Q1 2026, continuing a multi-year pattern of losses.
  • Operating cash flow was negative $9.4 million in Q1 2026, indicating ongoing cash burn from core operations.
  • Total liabilities of $108.4 million far exceed common equity of $13.3 million, highlighting financial leverage risk.
  • Interest expense remains heavy at $2.8 million in Q1 2026, pressuring bottom-line results.

Looking back over the last four years, the trend is mixed. Neuronetics has grown revenue substantially from the low-to-mid teens millions per quarter in 2024 to the mid-$30 million range in early 2026. But that growth has not yet translated into profitability. Net losses have persisted every quarter in the data provided, and operating cash flow has often been negative despite occasional quarters of financing support or working-capital help.

Bottom line: STIM is showing better revenue momentum, but the company still faces a difficult combination of losses, debt, and cash burn. For retail investors, the story remains one of execution and balance-sheet repair rather than near-term earnings strength.

07/12/26 07:03 PM ETAI Generated. May Contain Errors.

Neuronetics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Neuronetics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Neuronetics' net income appears to be on an upward trend, with a most recent value of -$39.14 million in 2025, rising from -$11.23 million in 2016. The previous period was -$43.73 million in 2024. Find out what analysts predict for Neuronetics in the coming months.

Neuronetics' total operating income in 2025 was -$31.44 million, based on the following breakdown:
  • Total Gross Profit: $72.31 million
  • Total Operating Expenses: $103.74 million

Over the last 9 years, Neuronetics' total revenue changed from $34.23 million in 2016 to $149.16 million in 2025, a change of 335.8%.

Neuronetics' total liabilities were at $115.31 million at the end of 2025, a 5.7% increase from 2024, and a 159.4% increase since 2017.

In the past 8 years, Neuronetics' cash and equivalents has ranged from $18.46 million in 2024 to $104.58 million in 2018, and is currently $28.13 million as of their latest financial filing in 2025.

Over the last 9 years, Neuronetics' book value per share changed from 0.00 in 2016 to 0.33 in 2025, a change of 32.7%.


Related Companies

Financial statements for NASDAQ:STIM last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
They proved it worked in '76. Then buried it.
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
When governments buy their own debt, gold miners move
On April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...
Golden Portfolio | Sponsoredtc pixel
The numbers don't add up
Warren Buffett's preferred market valuation tool just hit 217% - the highest reading ever recorded. Historical...
Thor Metals | Sponsoredtc pixel
Trump ordered the Army to do this…
Under Executive Order 14299, President Trump has ordered the U.S. Army and Department of Energy to launch a bo...
Banyan Hill Publishing | Sponsoredtc pixel